Literature DB >> 28246756

[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].

H Rexer1, J Bedke2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28246756     DOI： 10.1007/s00120-017-0335-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  6 in total

Review 1.  From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.

Authors:  Melissa Bersanelli; Sebastiano Buti
Journal:  World J Clin Oncol       Date:  2017-02-10

Review 2.  Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

Authors:  Thaiz Rivera Vargas; Lionel Apetoh
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 3.  Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.

Authors:  Maria Georganaki; Luuk van Hooren; Anna Dimberg
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 4.  The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.

Authors:  Omid Kooshkaki; Afshin Derakhshani; Hossein Safarpour; Souzan Najafi; Parviz Vahedi; Oronzo Brunetti; Mitra Torabi; Parisa Lotfinejad; Angelo Virgilio Paradiso; Vito Racanelli; Nicola Silvestris; Behzad Baradaran
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 5.  Immune checkpoint inhibitors in renal cell carcinoma.

Authors:  Kirsty Ross; Rob J Jones
Journal:  Clin Sci (Lond)       Date:  2017-10-27       Impact factor: 6.124

Review 6.  Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.

Authors:  Yiyi Yan; Anagha Bangalore Kumar; Heidi Finnes; Svetomir N Markovic; Sean Park; Roxana S Dronca; Haidong Dong
Journal:  Front Immunol       Date:  2018-07-27       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.